ACCESS for Biosimilars Act of 2019

referredUnited States· United States Congress· EN

Introduced

1 October 2019

Last action

2 October 2019 · Referred

Status

Referred to the Subcommittee on Health.

Summary

Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 or the ACCESS for Biosimilars Act of 2019 This bill eliminates cost-sharing for biosimilar biological products for certain qualifying beneficiaries under Medicare medical services. Specifically, the bill eliminates cost-sharing for beneficiaries whose coverage under private health insurance, a federal program (other than Medicare), a Medicare supplemental policy, or Medicare Advantage does not already do so. The Centers for Medicare & Medicaid Services must establish a process for determining a beneficiary's eligibility and notifying Medicare Advantage organizations of such determinations.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1 October 2019
Referred
Referred to the Subcommittee on Health.
Source: Committee
1 October 2019
Introduced
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Source: IntroReferral
1 October 2019
Introduced
Introduced in House
Source: IntroReferral
1 October 2019
Introduced
Introduced in House
Source: IntroReferral
2 October 2019
Referred
Referred to the Subcommittee on Health.
Source: Committee

Votes

No vote records are attached yet.

Versions

Introduced in House · 1 October 2019 · Download file

Documents

3 official files

Introduced in House (text)

View file Download file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Vertaal naar

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Introduced in House (text)
Introduced in House · EN · 1 October 2019
View Download Open at official source
Introduced in House (PDF)
Introduced in House · EN · 1 October 2019
View Download Open at official source
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Vertaal naar
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in House
summary · EN · 1 October 2019
Open at official source
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Vertaal naar
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Related records

related to ← Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2020

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.

Official source: https://www.congress.gov/bill/116th-congress/house-bill/4597
Open data entity: https://api.congress.gov/v3/bill/116/hr/4597
us · 116-hr-4597 · source updated 3 December 2025